MDSpire - Summary
Feature

CRISPR Enables In Vivo CAR T Cell Production

In vivo gene editing strategy generates CAR T cells directly inside the body – sidestepping costly manufacturing

  • March 30, 2026

  • 2 min

Share

Researchers have developed a novel CRISPR-based method that could revolutionize CAR T cell therapy by enabling the in vivo manufacture of engineered T cells. This two-vector system combines CRISPR-Cas9 with an adeno-associated virus (AAV) for precise gene insertion into T cells. In humanized mouse models, the technique effectively produced CAR T cells that not only proliferated but also exhibited significant anti-tumor activity against various cancers, potentially simplifying manufacturing processes and improving accessibility to effective therapies.

Original Source(s)

CRISPR Enables In Vivo CAR T Cell Production

  • March 30, 2026

Related Content

AI As Collaborator in Cancer Research and in Clinical Care

Last October, the Cancer AI Alliance (CAIA) announced the launch of its collaborative artificial intelligence (AI) platform powered by federated learning to train AI models with millions of de-identif...

Metabolic Subtypes of Nasopharyngeal Carcinoma and Response to Treatment

In a Chinese study reported in the Journal of Clinical Oncology, Huang et al developed a classification for metabolic subtypes of nasopharyngeal carcinoma that may help identify patients benefiting mo...

Diagnostics Explores the Fragmentome

An AI-augmented blood test detects early liver fibrosis and other diseases

  • March 30, 2026

  • 5 min